AU8118398A - Identification of mhc binding peptides - Google Patents

Identification of mhc binding peptides

Info

Publication number
AU8118398A
AU8118398A AU81183/98A AU8118398A AU8118398A AU 8118398 A AU8118398 A AU 8118398A AU 81183/98 A AU81183/98 A AU 81183/98A AU 8118398 A AU8118398 A AU 8118398A AU 8118398 A AU8118398 A AU 8118398A
Authority
AU
Australia
Prior art keywords
identification
binding peptides
mhc binding
mhc
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU81183/98A
Inventor
Tony Brooks
Frank Carr
John Fothergill
Graham Kemp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovation Ltd
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovation Ltd filed Critical Biovation Ltd
Publication of AU8118398A publication Critical patent/AU8118398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
AU81183/98A 1997-06-20 1998-06-19 Identification of mhc binding peptides Abandoned AU8118398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9712892 1997-06-20
GBGB9712892.0A GB9712892D0 (en) 1997-06-20 1997-06-20 Identification of mhc binding peptides
PCT/GB1998/001801 WO1998059244A1 (en) 1997-06-20 1998-06-19 Identification of mhc binding peptides

Publications (1)

Publication Number Publication Date
AU8118398A true AU8118398A (en) 1999-01-04

Family

ID=10814539

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81183/98A Abandoned AU8118398A (en) 1997-06-20 1998-06-19 Identification of mhc binding peptides

Country Status (3)

Country Link
AU (1) AU8118398A (en)
GB (1) GB9712892D0 (en)
WO (1) WO1998059244A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072291A1 (en) * 2001-02-06 2004-04-15 Carr Francis J. Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
RU2003125641A (en) 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Modified Colony Stimulating Granulocyte Factor (G-CSF) with Reduced Immunogenicity
EP1366074B1 (en) 2001-03-08 2006-09-13 MERCK PATENT GmbH Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
HUP0303523A3 (en) * 2001-03-20 2005-12-28 Merck Patent Gmbh Modified insulin with reduced immunogenicity
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20050020494A1 (en) * 2001-09-04 2005-01-27 Carr Francis J Modified human growth hormone
ES2319758T3 (en) * 2002-04-18 2009-05-12 Merck Patent Gmbh MODIFIED FACTOR VIII.
EP1516275B1 (en) 2002-06-10 2007-03-07 AlgoNomics N.V. Method for predicting the binding affinity of mhc/peptide complexes
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
AU2004227937B2 (en) * 2003-03-31 2007-09-20 Xencor, Inc Methods for rational pegylation of proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
JP4804357B2 (en) 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー Modified anti-CD52 antibody
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
ES2530340T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
FI20060200A0 (en) * 2005-04-20 2006-02-27 Glykos Finland Oy Method for analyzing the specificity of sialic acid binding of human influenza virus
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
DK2270050T3 (en) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19 antibodies with reduced immunogenicity
US8396671B2 (en) 2006-02-16 2013-03-12 Microsoft Corporation Cluster modeling, and learning cluster specific parameters of an adaptive double threading model
US20070192033A1 (en) 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
US8706421B2 (en) 2006-02-16 2014-04-22 Microsoft Corporation Shift-invariant predictions
WO2008025015A2 (en) * 2006-08-25 2008-02-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epitope-protein scaffolds and their use
US8121797B2 (en) 2007-01-12 2012-02-21 Microsoft Corporation T-cell epitope prediction
CN101848719B (en) * 2007-06-25 2015-09-23 图兰恩教育基金管理人 Influenza inhibiting compositions and method
EP2296688A2 (en) * 2007-10-26 2011-03-23 Glykos Finland Oy Peptide vaccine for influenza virus
EP3575317A1 (en) 2007-12-26 2019-12-04 Xencor, Inc. Fc variants with altered binding to fcrn
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
EP2793944A4 (en) 2011-12-23 2015-09-02 Nicholas B Lydon Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
AU2013290424B2 (en) 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
EP3530284B1 (en) 2012-12-26 2023-10-25 OncoSynergy, Inc. Anti-integrin beta1 antibody compositions and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
ES2162917T3 (en) * 1994-05-13 2002-01-16 Biovation Ltd IMPROVEMENTS IN OR RELATING TO THE SUPPLY OF PEPTIDES.

Also Published As

Publication number Publication date
GB9712892D0 (en) 1997-08-20
WO1998059244A1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
AU8118398A (en) Identification of mhc binding peptides
AU7542498A (en) Nucleic acid binding proteins
AU6030398A (en) Human proteins
EP0897707A3 (en) Compression system
AU4922497A (en) Interleukin-18-receptor proteins
AU6868398A (en) Mu-opiate receptor peptides
AU8466498A (en) Ski binding
AU3216797A (en) Novel heparin binding peptides
AU2091799A (en) Uses of alpha-conotoxin peptides
AU7694898A (en) Ubiquitin conjugation proteins
AU8596498A (en) Annexin binding protein
AU3640397A (en) Ob protein binding protein
AU1235597A (en) Fibrinogen binding peptides
AU1999999A (en) Contryphan peptides
AU7410598A (en) Novel human RNA binding protein
AU9192198A (en) Identification system
AU6035298A (en) Human zinc binding proteins
AU6000698A (en) Proteins
AU5384698A (en) Anti-obesity proteins
GB9714276D0 (en) Peptides and related compounds
AU4586497A (en) Calcium-integrin binding protein
AU6275098A (en) Novel h-rev 107-like protein
AU7954998A (en) Cyclin related proteins
AU8030098A (en) Polypeptide presentation system
AU8063298A (en) Human formin binding protein